Compare TEX & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | BLLN |
|---|---|---|
| Founded | 1933 | 2016 |
| Country | United States | United States |
| Employees | 10700 | 713 |
| Industry | Construction/Ag Equipment/Trucks | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.0B |
| IPO Year | 1994 | N/A |
| Metric | TEX | BLLN |
|---|---|---|
| Price | $64.53 | $131.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 7 |
| Target Price | $68.80 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 1.4M | 706.5K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,421,000,000.00 | N/A |
| Revenue This Year | $47.67 | $46.29 |
| Revenue Next Year | $6.66 | $30.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $41.70 | $61.96 |
| 52 Week High | $74.69 | $138.70 |
| Indicator | TEX | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 64.49 |
| Support Level | $58.54 | $79.07 |
| Resistance Level | $66.33 | $138.70 |
| Average True Range (ATR) | 3.05 | 7.07 |
| MACD | -0.68 | -0.17 |
| Stochastic Oscillator | 18.36 | 92.55 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.